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Because of its large size (MW 825 dal-
tons) and its susceptibility to transport 
by Mrp1 and Pgp, vincristine has poor 
blood-brain barrier (BBB) penetrance (4,5). 
Therefore, its use for the treatment of CNS 
tumors has been questioned (4,6). Vincris-
tine also has significant dose-limiting  toxici-
ties. The peripheral neuropathies resulting 
from its use can be debilitating and perma-
nent, often halting use of the drug (7,8).
Mebendazole, an anthelmintic with a 
rather benign side effect profile that has 
been in longstanding clinical use, has re-
cently been shown to display significant 
therapeutic efficacy in animal models of 
both glioblastoma and medulloblastoma 
(9,10). Depending on crystallization con-
ditions, mebendazole can form three  
tumors. Along with procarbazine and 
lomustine (CCNU), it constitutes the PCV 
regimen, which is currently considered 
standard of care for newly diagnosed  
patients with 1p/19q co-deleted anaplastic 
oligodendroglioma (1,2) and adult patients 
with low-grade glioma (3).
iNtRODUCtiON
The microtubule polymerization inhibi-
tor vincristine has a broad spectrum of use 
in cancer chemotherapy, for both hema-
tological malignancies and solid tumors. 
Vincristine is also used in the treatment of 
a variety of central nervous system (CNS) 
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different polymorphs, termed A, B and C, 
which display significant differences in 
bioavailability (11,12). As a result, the 
distinct polymorphs, when adminis-
tered orally, also have different toxicity 
and therapeutic effects, as both anthel-
mintic and anticancer agents (11,12). 
However, once dissolved, the respective 
polymorphs have identical properties. 
Both polymorphs B and C have good 
bioavailability and BBB penetration and 
display similar therapeutic efficacy in 
the GL261-C57BL/6 glioblastoma model, 
whereas polymorph A totally lacks in 
efficacy (12).
Mebendazole has been shown to 
inhibit microtubule formation (9,13), 
but it is not known whether its tumor 
cell–killing effect is solely mediated by 
its microtubule destabilizing effect. In-
deed, mebendazole has been shown to 
inhibit a number of protein kinases (14). 
In this study, therefore, we examined 
the mechanisms of tumor cell killing of 
mebendazole in detail, motivated by 
the possibility that mebendazole may 
be able to serve as a safer and more ef-
fective replacement for vincristine for 
the treatment of brain tumors. Thus, 
we determined the inhibitory effects of 
mebendazole on GL261 glioblastoma cell 
viability, metaphase arrest and microtu-
bule polymerization and compared these 
effects with those of vincristine. We also 
compared the therapeutic efficacies and 
toxicities of mebendazole and vincristine 
in the GL261-C57BL/6 syngeneic orthot-
opic mouse model.
MAteRiALS AND MetHODS
tissue Culture
The GL261 glioblastoma cell line was 
maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and antibi-
otics. All cells were maintained at 37°C 
in humidified air containing 5% CO2.
Cytotoxicity Assay
GL261 cells were seeded in 96-well tis-
sue culture plates at 3,000 cells per well. 
After 24 h, cells were treated with a range 
of concentrations of either mebendazole 
or vincristine for 96 h, with a medium 
change at 72 h. At 96 h, an MTT assay 
(Sigma) was performed and cell viability 
was determined by absorbance at  
595 nm.
tubulin Polymerization Assay
The tubulin polymerization assay was 
performed essentially as described (15). 
In brief, GL261 glioblastoma cells were 
seeded at 3 × 105 cells per well in 6-well 
tissue culture plates. The next day, cells 
were treated with a range of concentra-
tions of either mebendazole or vincris-
tine for 24 h. Subsequently, the cells were 
rinsed in PBS at 22°C and harvested at 
the same temperature in hypotonic lysis 
buffer (1 mM MgCl2, 2 mM EGTA,  
0.5% NP-40, 20 mM Tris HCl pH 6.8) 
containing protease inhibitors and ben-
zonase. The samples were centrifuged 
at 13,000g for 10 min at 22°C to separate 
polymerized (P) from soluble (S) tubulin. 
The supernatant containing the depo-
lymerized (S) tubulin was transferred to 
a new tube. The pellet containing polym-
erized (P) tubulin was resuspended in an 
equal amount of hypotonic lysis buffer. 
Equal amounts of protein were loaded 
on sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) 
gels and analyzed by western blotting 
with anti–α-tubulin and GAPDH anti-
bodies using chemiluminescence (Amer-
sham ECL Western Blotting System, GE 
Healthcare). The blots were scanned  
and quantified using ImageJ 1.44p  
(National Institutes of Health). Microtu-
bule polymerization was determined as 
the percentage of polymerized tubulin 
over total tubulin.
immunofluorescence
GL261 cells were seeded at a density of 
30,000 cells per well in 24-well plates con-
taining coverslips coated with 0.1 mg/mL 
high-molecular-weight polylysine (Sigma) 
and subsequently with 0.5 μg/cm2 lami-
nin from Engelbreth-Holm-Swarm 
murine sarcoma (Sigma). The follow-
ing day, cells were exposed to 6 Gy of 
X-ray radiation. At designated time 
points post-IR, cells were washed in 
PBS and fixed in 4% formaldehyde in 
PBS at room temperature. Once the 
cells were fixed, immunofluorescence 
was performed using an MPM2 anti-
body (Millipore) and counterstained 
with DAPI. For each condition, a total 
of 10 fluorescence micrograph images 
were taken with a Zeiss Axiovert 200M 
inverted microscope running on Axio-
vision software. For each image field, 
the total number of cells and the num-
ber of MPM2-positive cells were quan-
tified. The mitotic index was calculated 
at each time point using the number of 
MPM2-positive cells as a percentage of 
the total number of cells counted in all 
10 fields.
Luciferase expression by Lentivirus
The pLenti-UBC-Gluc-T2A-Puro  
lentiplasmid was purchased from 
Targeting Systems. This plasmid was 
transfected into 293NT cells, along with 
plasmids carrying the virus reverse 
transcriptase gene (REV), the envelope 
glycoprotein gene (VSV-G) and the 
polymerase gene (GAG-Pol), using Lipo-
fectamine 2000 (Invitrogen). Virus was 
harvested after 48 h and used to infect 
GL261 cells to make GL261/GLuc.
Animal experiments
Female C57BL/6 mice (age 3 months) 
were purchased from Jackson Labs. The 
transduced GL261/GLuc cells were used 
for brain tumor implantation. Tumor 
cells (20,000/2 μL) were implanted using 
a stereotactic frame through a burr hole 
drilled 2 mm lateral to the bregma and  
1 mm posterior to the coronal suture at a 
depth of 3 mm below the dura at a rate 
of 1 μL/min.
Tail vein blood was collected daily and 
used for Gaussia luciferase quantifica-
tion by luminometry assay as previously 
described (16). Gaussia luciferase sub-
strate was purchased through Targeting 
Systems. Mice were randomly assigned 
to four different treatment groups once 
their G-luciferase values exceeded 1.3. 
Mebendazole was administered by oral 
gavage. Vincristine was administered 
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is subject to considerable variability. 
Therefore, to further examine the  
correlation between the effects of me-
bendazole on cytotoxicity microtubule 
depolymerization, we also determined 
the EC50 of both mebendazole and 
vincristine to induce mitotic arrest, a 
process that is critically dependent on 
microtubule formation. To determine 
the fraction of cells that are in the mi-
totic phase of the cell cycle, we used the 
MPM2 monoclonal antibody that binds 
to a phosphoamino acid–containing 
epitope present on multiple proteins 
during mitosis (18). Using this method, 
we first determined the time depen-
dence of mitotic cell accumulation using 
a saturating concentration (500 nM) 
of mebendazole. We found that upon 
addition of mebendazole, the number 
of mitotic cells steadily increased over 
the first 8 h and reached a plateau by 
24 h (Figure 2A). Next, using an incu-
by its inhibitory effect on microtubule 
formation, we compared the relative po-
tencies of mebendazole and vincristine 
on microtubule formation and cell via-
bility in GL261 glioma cells. Microtubule 
formation was quantified by hypotonic 
lysis of cells, followed by separation of 
polymerized and unpolymerized tubulin 
in the pellet and supernatant fractions, 
respectively (15). Cell viability was deter-
mined using the MTT assay.
From the data shown in Figure 1, we 
determined that the half maximal effec-
tive concentration (EC50) of mebendazole 
for microtubule depolymerization  
(132 nM) is very similar to that for cell 
viability (160 nM). A similar relationship 
holds for vincristine, although the differ-
ence between the EC50 for microtubule 
depolymerization (1.36 nM) and that for 
cell viability (2 nM) is slightly larger.
As noted previously (15), the cellu-
lar microtubule polymerization assay 
by intraperitoneal injection. Polymorph 
C mebendazole tablets (S2017, Au-
rochem Laboratories Ltd.) were a gift 
from G. Riggins, Johns Hopkins Univer-
sity School of Medicine. Tablets were 
grounded into powder and resuspended 
in a PBS/sesame oil (50% v/v) mixture 
to achieve better gastrointestinal absorp-
tion of the drug. The gavage tip was 
coated with agave syrup prior to admin-
istration. Mebendazole suspensions were 
made fresh weekly.
Animals were observed daily for any 
signs of deterioration, neurotoxicity, 
movement disorders or signs of pain and 
distress in accordance with our Institu-
tional Animal Care and Use Committee 
protocols, and euthanized when symp-
toms appeared.
Von Frey Filament testing
Allodynia was determined essentially 
as described (17). Briefly, the mouse 
plantar surface of the hind paw was 
probed with calibrated von Frey hairs, 
with bending forces from 8 mg to 4 g. 
The 50% withdrawal threshold (the force 
of the von Frey hair, in grams, to which 
the animal reacts in 50% of instances) 
was determined by applying the hairs six 
times. Time between measurements was 
at least 30 s between alternating paws. 
Comparison to baseline sensitivity was 
used to determine significant decrease in 
the withdrawal threshold.
Statistical Analysis
Direct comparisons were conducted 
using unpaired two-tailed Student t test. 
Statistical analysis was performed using 
GraphPad Prism 6 Software. A P value 
lower than 0.05 was considered signifi-
cant. The Kaplan-Meier estimate and a 
log-rank (Mantel-Cox) test were used to 
generate survival curves with the Graph-
Pad Prism 6.0 software.
ReSULtS
Mebendazole and Vincristine Have 
Similar Cellular Mechanisms of Action
To examine whether the cytotoxic ef-
fects of mebendazole are indeed caused 
Figure 1. Mebendazole and vincristine have similar inhibitory effects on cell viability and 
microtubule polymerization. (A,B) Western blots illustrating microtubule depolymerization 
caused by incubation of GL261 cells with the indicated concentrations of mebendazole 
(MBZ) and vincristine (VCR). Cells were processed, and polymerized (P) and soluble (S) 
tubulin were separated by centrifugation as described in Materials and Methods. (C,D) 
Concentration dependence of microtubule polymerization and cell viability: (C) meben-
dazole, (D) vincristine. Microtubule polymerization was determined as the percentage 
of polymerized tubulin over total tubulin. Determination of cell viability was performed as 
described in Materials and Methods. Data shown were normalized to vehicle control val-
ues and represent the mean ± SEM of three and at least eight independent experiments 
for the microtubule polymerization and cell viability experiments, respectively.
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bation time of 8 h, we determined the 
respective EC50 values of mebendazole 
and vincristine for mitotic arrest to be 
192 nM and 2.49 nM (Figures 2B, C). 
Remarkably, the ratio of the EC50 for mi-
totic arrest over the EC50 for cell viability 
for mebendazole (1.20) is very similar 
to that for vincristine (1.24). Thus, the 
data obtained with this more accurate 
method of probing cellular microtubule 
function strongly support the hypothesis 
that the cellular mechanisms of action of 
mebendazole and vincristine are indeed 
identical.
To further probe the mechanism of 
action of mebendazole, we used the 
COMPARE search tool of the NCI De-
velopmental Therapeutics Program to 
find drugs that have similar mechanisms 
of toxicity in a set of 59 different human 
tumor cell lines that cover 9 different 
tissue types, including brain (19,20). Of 
the 20 highest-scoring compounds with 
known mechanisms of action, 70% have 
been shown to modulate microtubule 
dynamics, including vinblastine, taxol, 
colchicine and lesser known drugs such 
as rhizoxin, podophyllotoxin and may-
tansine. Thus, this analysis provides fur-
ther evidence that the major mechanism 
of action of mebendazole is microtubule 
destabilization.
Mebendazole, but Not Vincristine, 
Promotes the Survival of Glioma-
Bearing Mice
With regard to therapeutic efficacy, it 
is important to note that, depending on 
crystallization conditions, mebendazole 
can form three different polymorphs, 
termed A, B and C, which display sig-
nificant differences in solubility and 
bioavailability (11,12). As a result, the 
distinct polymorphs, when administered 
orally, also have different toxicity and 
therapeutic effects, as both anthelmintic 
and anticancer agents (11,12). However, 
once dissolved, the respective poly-
morphs have identical properties. As has 
been shown recently, polymorphs B and 
C display similar therapeutic efficacy in 
the GL261-C57BL/6 model, with poly-
morph C being slightly more effective 
than polymorph B, and polymorph A 
totally lacking in efficacy (12). In this 
study, therefore, for all in vivo experi-
ments, we used polymorph C.
For the animal studies, we per-
formed orthotopic implantation of 
the GL261 cells in syngeneic C57BL/6 
mice. To monitor tumor formation, 
we first transduced GL261 cells with 
Gaussia luciferase (Gluc), a secreted 
luciferase that can be quantified using 
a small volume of blood (16). Tail vein 
blood was collected every 1–3 d, and 
mice were randomized and treatments 
started once Gluc levels reached a pre-
determined value that corresponded 
to approximately 10 d after tumor cell 
implantation, as determined from pilot 
studies.
To determine the relative therapeutic 
efficacies of mebendazole and vincristine 
in mice, we used two doses for each drug. 
In the literature, values for the maximum 
Figure 2. Mebendazole and vincristine 
induce metaphase arrest with a similar 
concentration dependence as that of 
cell viability. (A) Time dependence of 
mebendazole-induced metaphase ar-
rest. Mebendazole concentration was 
500 nM. Data shown represent the  
mean ± SEM of three independent exper-
iments. (B,C) Concentration dependence 
of metaphase arrest: (B) mebendazole, 
(C) vincristine. Data shown represent the 
mean ± SEM of three independent  
experiments.
Figure 3. Mebendazole, but not vincristine, promotes the survival of glioma-bearing  
mice. Kaplan-Meier survival curves of mice implanted with GL261 glioma cells and 
treated with different doses of mebendazole and vincristine. Group sizes of the respec-
tive groups are 11–12.
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We have provided two independent 
lines of evidence indicating that the 
cytotoxicity of mebendazole is caused 
by its inhibitory effect on microtubule 
polymerization. First, the EC50 for me-
bendazole-induced cell toxicity is very 
similar to that of microtubule depo-
lymerization and metaphase arrest.  
In addition, the same relationships be-
tween the EC50 values for mebendazole 
for cell toxicity, microtubule depolym-
erization and metaphase arrest hold 
for the effects of vincristine on these 
administration of mebendazole or vin-
cristine as monotherapy caused minor 
weight loss over this time period.
DiSCUSSiON
Our in vitro analysis strongly indicates 
that the mechanisms of cell killing by 
mebendazole are identical to those of 
vincristine. We also show that, whereas 
mebendazole has a significant therapeu-
tic effect in the GL261-C57BL/6 model, 
vincristine has no efficacy at all in this 
model.
tolerated dose (MTD) of vincristine  
for mice range from 1.17 to 1.5 mg/kg 
(21–23). Therefore, we chose to examine 
the effects of 0.5 and 1.0 mg/kg of vin-
cristine. Dosing for mebendazole is less 
extensively documented in the literature. 
In one study, daily oral administration 
of mebendazole at 50 mg/kg was shown 
to be well tolerated, whereas a dose of 
100 mg/kg showed apparent toxicity, as 
indicated by weight loss (9). However, as 
our pilot experiments did not reveal any 
toxicity at the higher dose of 100 mg/kg,  
we included both 50 mg/kg and 100 mg/kg  
in this study.
The control group had a mean survival 
of 10.1 d after treatment onset (95% con-
fidence interval [CI], 9.2–11, Figure 3). 
Weekly intraperitoneal administration 
of vincristine at either 0.5 mg/kg (mean 
survival of 11 d, 95% CI, 10.16–11.8) 
or 1.0 mg/kg (mean survival of 11.9 d, 
95% CI, 8.9–14.9)  did not show a sig-
nificant survival benefit. Daily oral 
gavage of mebendazole, however, sig-
nificantly enhanced animal survival with 
both 50 mg/kg (mean survival of 17 d, 
95% CI, 13.4–20.6) and 100 mg/kg (mean 
survival of 19 d, 95% CI, 15.3–22.9).
Peripheral neuropathy is a major 
side effect of vincristine and other mi-
crotubule drugs in the clinic. Thus, to 
quantify drug toxicity, we also examined 
the emergence of sensory allodynia by 
measuring footpad sensitivity using von 
Frey filaments. As paw withdrawal may 
be modulated by the presence of brain 
tumors, we performed an additional 
study in non–tumor-bearing animals. 
As expected, vincristine caused a sig-
nificant increase in footpad sensitivity 
(Figure 4A). Mebendazole caused a ten-
dency toward increased footpad sensi-
tivity, but this increase was not statistically 
significant. We also examined the  
toxicity of combined mebendazole and 
vincristine. Combined administration 
of both drugs caused rapid weight loss 
after less than 1 wk (Figure 4B), trig-
gering euthanasia of the animals. Com-
bining mebendazole with vincristine 
also appeared to further increase the 
emergence of neuropathy. In contrast, 
Figure 4. Drug-induced toxicities. (A) Peripheral neuropathy in mebendazole- and vincristine- 
treated mice. Shown are the mean ± SEM (n = 12) of footpad sensitivity measurements using 
von Frey filaments on d 6 after treatment initiation. (B) Animal weights before and during 
treatment. Data points represent the weight averages for each group ± SEM (n = 12).
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(PCV) to treat a wide range of brain 
tumors (28). The introduction of this 
combination was based on the thera-
peutic activity of procarbazine in an 
intracerebral rat leukemia model (29) 
and that of CCNU in orthotopic models 
of glioma and ependymoblastoma (30). 
Including vincristine in this regimen 
was based on limited clinical expe-
rience in a small number of patients 
(31,32).
CONCLUSiON
Our findings documenting a lack of 
therapeutic efficacy of vincristine in 
a mouse model for glioma where me-
bendazole shows significant efficacy, 
in addition to a lack of evidence for the 
clinical benefit of vincristine in the treat-
ment of brain tumors, strongly suggest 
that vincristine should not be used che-
motherapeutically in neuro-oncology. 
Thus, as mebendazole and vincristine 
have the same mechanism of action, 
replacing vincristine with mebendazole 
may facilitate the elimination of vincris-
tine from neuro-oncological regimens.
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